tbuckley/cabot-search huggingface dataset:
Patient preferences for chemotherapies used in breast cancer.
Authors: K. Beusterien, J. Grinspan, T. Tencer, A. Brufsky, C. Visovsky
Journal: Journal of Clinical Oncology (2011)

e19667 Background: New therapies are being developed for advanced breast cancer that may not be curative, but may be associated with an incremental advantage in survival relative to existing therapies. This increase in survival duration should be weighed against the risk of toxicities when making treatment decisions. The objective of this study was to assess the trade-offs patients are willing to make among efficacy, administration regimen, and risk of toxicities among available advanced breast cancer therapies. Methods: This was a cross-sectional study of 121 subjects with Stage I through Stage IV breast cancer. Participants completed a Web-based adaptive conjoint analysis (ACA) survey that assessed the following attributes of currently available advanced breast cancer treatments: 10 grade III/IV toxicities, survival advantage, and administration regimen. Literature, expert input, and patient support forums on the Web were used to identify percentage risks and descriptions for each attribute. Subjects indicated their preferences in pair-wise comparisons of different hypothetical treatments. Ordinary least-squares regression was used to calculate utilities (preference weights) for each attribute level (% risk of toxicity, additional months of survival, regimen). Attribute utilities were summed for each product profile to determine the most preferred treatment. Results: Of the 12 chemotherapy attributes evaluated, survival was the most important attribute; specifically, a survival advantage of 3 months versus no advantage was most influential in the perceived value of a chemotherapy. Among chemotherapies, the difference in the risks of neutropenia, gastrointestinal disturbances (diarrhea, nausea), and fatigue had the most impact on treatment preferences; the difference in the risks of myalgia, mucositis/stomatitis, and hand-foot syndrome had the least. A more convenient administration regimen was less important than a 13% chance or more of severe toxicities but more important than a 10-12% chance of severe toxicities. Conclusions: Breast cancer patients highly value small incremental survival advantages associated with treatment, despite the risk of serious toxicities.
Quantification of Regulatory/Effector CD4+ T Lymphocytes Pre and Post-Treatment in Patients with Classical Hodgkin Lymphoma in Brazil
Authors: Joyce M. K. Silva, Adriana M. Damasco Penna, Maria Mirtes Sales, Elma Maria Chaves, Priscilla Brito Silva, Mariane Cristina Gennari Assis, Otávio Cesar Carvalho Guimarães Baiocchi
Journal: Blood (2012)
A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia
Authors: Kerry A. Rogers, Galena Salem, Deborah M. Stephens, Leslie A. Andritsos, Farrukh T. Awan, John C. Byrd, Joseph M. Flynn, Kami J. Maddocks, Ying Huang, Amy S. Ruppert, Jeffrey A. Jones
Journal: Blood (2015)
Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience
Authors: Fiorina Giona, Giuseppe Saglio, Michelina Santopietro, Giuseppe Menna, Grazia Iaria, Maria Caterina Putti, Concetta Micalizzi, Nicola Santoro, Saverio Ladogana, Rosa Maria Mura, Roberta Burnelli, Caterina Consarino, Carlo Cosmi, Maria Luisa Moleti, Stefania Varotto, Francesca Tucci, Mauro Nanni, Daniela Diverio, Andrea Biondi, Franco Locatelli, Robin Foà
Journal: Blood (2015)
WT-1 Over-Expression Could Be Related to " High Metaplastic Index" in Myelofibrosis with Myeloid Metaplasia (MMM) Patients. A Preliminary Report.
Authors: Francesco Iuliano, Daniela Cilloni, Enrico Gottardi, Milena Fava, Flora Fabiano, Antonio Peta, Giuseppe Saglio
Journal: Blood (2004)
Behavioral and Pharmacological Strategies for Weakening Maladaptive Reward Memories
Authors: Sunjeev K. Kamboj, Ravi K. Das
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Does Declining Mitochondrial NAD+ and Unscheduled Opening of Mitochondrial Transition Pore Promote Mammalian Aging?
Authors: David Sinclair, Angela V. Hafner, Ana Gomes, Jing Liang, Yana Cen, Ian Lanza, Sree Nair, Anthony Sauve, Anthony Rozenzweig
Journal: Blood (2010)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
Authors: W. Fraser Symmans, Caimiao Wei, Rebekah Gould, Xian Yu, Ya Zhang, Mei Liu, Andrew Walls, Alex Bousamra, Maheshwari Ramineni, Bruno Sinn, Kelly Hunt, Thomas A. Buchholz, Vicente Valero, Aman U. Buzdar, Wei Yang, Abenaa M. Brewster, Stacy Moulder, Lajos Pusztai, Christos Hatzis, Gabriel N. Hortobagyi
Journal: Journal of Clinical Oncology (2017)

Purpose To determine the long-term prognosis in each phenotypic subset of breast cancer related to residual cancer burden (RCB) after neoadjuvant chemotherapy alone, or with concurrent human epidermal growth factor receptor 2 (HER2)-targeted treatment. Methods We conducted a pathologic review to measure the continuous RCB index (wherein pathologic complete response has RCB = 0; residual disease is categorized into three predefined classes of RCB index [RCB-I, RCB-II, and RCB-III]), and yp-stage of residual disease. Patients were prospectively observed for survival. Three patient cohorts received paclitaxel (T) followed by fluorouracil, doxorubicin, and cyclophosphamide (T/FAC): original development cohort (T/FAC-1), validation cohort (T/FAC-2), and independent validation cohort (T/FAC-3). Another validation cohort received FAC chemotherapy only, and a fifth cohort received concurrent trastuzumab (H) with sequential paclitaxel and fluorouracil, epirubicin, and cyclophosphamide (FEC; H+T/FEC). Phenotypic subsets were defined by hormone receptor (HR) and HER2 status at diagnosis, classified as HR-positive/HER2-negative, HER2-positive (HR-negative/HER2-positive or HR-positive/HER2-positive), or triple receptor-negative. Relapse-free survival estimates were determined from Kaplan-Meier analysis and compared using the log-rank test. Results Five cohorts (T/FAC-1 [n = 219], T/FAC-2 [n = 262], T/FAC-3 [n = 342], FAC [n = 132], and H+T/FEC [n = 203]) had median event-free follow-up of 13.5, 9.1, 6.8, 16.4, and 7.1 years, respectively. Continuous RCB index was prognostic within each phenotypic subset, independent of other clinical-pathologic variables. RCB classes stratified prognostic risk overall, within each phenotypic subset, and within yp-stage categories. Estimates of 10-year relapse-free survival rates in the four RCB classes (pathologic complete response, RCB-I, RCB-II, and RCB-III) were 86%, 81%, 55%, and 23% for triple receptor-negative; 83%, 97%, 74%, and 52% for HR-positive/HER2-negative in the combined T/FAC cohorts; and 95%, 77%, 47%, and 21% in the H+T/FEC cohort. Conclusion RCB was prognostic for long-term survival after neoadjuvant chemotherapy in all three phenotypic subsets of breast cancer. Our institutional findings should be externally validated.
The Target Genes and Prognostic Significance of Mir-150 in Chronic Lymphocytic Leukemia
Authors: Marek Mraz, Laura Z. Rassenti, Emanuela M. Ghia, Liguang Chen, Jessie-Farah Fecteau, Sarka Pospisilova, Hongying Li, Karen Messer, Thomas J. Kipps
Journal: Blood (2012)
Early Results of a Phase II Trial Testing Low Dose Total Body Irradiation (LTBI) after Chemoimmunotherapy in Elderly High Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Akmal Safwat, Lena Specht, Flemming Hansen, Mads Hansen, Jesper Jurlander, Anne Marie Boesen, Francesco d’Amore
Journal: Blood (2007)
Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience
Authors: Adrian Alegre, Albert Oriol-Rocafiguera, Jose García-Laraña, María-Victoria Mateos, Anna Sureda, Carmen Martínez Chamorro, María Teresa Cibeira, Robert Knight, Barbara Rosettani
Journal: Blood (2010)
Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD
Authors: Markus P. Schneider, Ulrike Raff, Christoph Kopp, Johannes B. Scheppach, Sebastian Toncar, Christoph Wanner, Georg Schlieper, Turgay Saritas, Jürgen Floege, Matthias Schmid, Anna Birukov, Anke Dahlmann, Peter Linz, Rolf Janka, Michael Uder, Roland E. Schmieder, Jens M. Titze, Kai-Uwe Eckardt
Journal: Journal of the American Society of Nephrology (2017)

The pathogenesis of left ventricular hypertrophy in patients with CKD is incompletely understood. Sodium intake, which is usually assessed by measuring urinary sodium excretion, has been inconsistently linked with left ventricular hypertrophy. However, tissues such as skin and muscle may store sodium. Using 23sodium-magnetic resonance imaging, a technique recently developed for the assessment of tissue sodium content in humans, we determined skin sodium content at the level of the calf in 99 patients with mild to moderate CKD (42 women; median [range] age, 65 [23-78] years). We also assessed total body overhydration (bioimpedance spectroscopy), 24-hour BP, and left ventricular mass (cardiac magnetic resonance imaging). Skin sodium content, but not total body overhydration, correlated with systolic BP (r=0.33, P=0.002). Moreover, skin sodium content correlated more strongly than total body overhydration did with left ventricular mass (r=0.56, P<0.001 versus r=0.35, P<0.001; P<0.01 between the two correlations). Linear regression analysis demonstrated that skin sodium content is a strong explanatory variable for left ventricular mass, unaffected by BP and total body overhydration. In conclusion, we found skin sodium content to be closely linked to left ventricular mass in patients with CKD. Interventions that reduce skin sodium content might improve cardiovascular outcomes in these patients.
<scp>IL</scp> ‐17A localizes in the exocytic compartment of mast cells in psoriatic skin
Authors: N.C. Brembilla, R. Stalder, L. Senra, W.‐H. Boehncke
Journal: British Journal of Dermatology (2017)

Psoriasis is a frequent, chronic recurrent inflammatory skin disease that substantially affects the quality of life of patients. IL-17A is believed to play a major role in its pathogenesis, as strategies to block this cytokine proved to be particularly effective in the treatment of psoriasis1. However, the cellular sources of IL-17A in psoriasis are still debated. Th17 cells have been suggested as major contributors2,3, although this hypothesis has been recently challenged by the histological analysis of lesional psoriatic skin from several independent groups. In the epidermis, neutrophils – forming the so-called Munro's microabscesses – stain strongly positive for IL-17A, while in the dermal compartment IL-17A is mainly found in mast cells, less so in neutrophils and only rarely in T cells3-5.

This article is protected by copyright. All rights reserved.
Thalidomide, Dexamethasone and Pegylated-Liposomal Doxorubicin (ThaDD) for Untreated Multiple Myeloma Patients Aged over 65 Years.
Authors: Massimo Offidani, Laura Corvatta, Monica Marconi, Giuseppe Visani, Francesco Alesiani, Marino Brunori, Piero Galieni, Massimo Catarini, Maurizio Burattini, Riccardo Centurioni, Serena Rupoli, Anna Rita Scortechini, Luciano Giuliodori, Marco Candela, Debora Capelli, Mauro Montanari, Attilio Olivieri, Maria-Novella Piersantelli, Pietro Leoni
Journal: Blood (2005)
T-Cell Receptor Gene Deletions Are Associated with High Risk Features and Worse Outcome In Childhood Precursor B-Cell Acute Lymphoblastic Leukemia (ALL)
Authors: Jonathan Downie, Phillip Barnette, Vladimir Rodic, J. Kimble Frazer, Nikolaus Trede, Meenakshi Devidas, Charles Mullighan, Stephen Hunger, Rodney R. Miles, Joshua D. Schiffman
Journal: Blood (2010)
Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia
Authors: J G Sfeir, M T Drake, B R LaPlant, M J Maurer, B K Link, T J Berndt, T D Shanafelt, J R Cerhan, T M Habermann, A L Feldman, T Witzig
Journal: Blood Cancer Journal (2017)

Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia
IMPS-25DIFFERENTIAL TUMOR MICROENVIRONMENTS AND RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN MOLECULAR SUBTYPES OF MURINE MEDULLOBLASTOMA
Authors: Christina Pham, Catherine Flores, Changlin Yang, Elias Sayour, Yanxin Pei, Colin Moore, Roger McLendon, Jianping Huang, John Sampson, Robert Wechsler-Reya, Duane Mitchell
Journal: Neuro-Oncology (2015)

PURPOSE: Despite significant strides in the identification and characterization of potential therapeutic targets for medulloblastoma (MB), the role of the immune system and its interplay with the tumor microenvironment within these tumors are poorly understood. To address this, we adapted two syngeneic animal models of human Sonic Hedgehog (SHH)-driven and Group 3 MB for preclinical evaluation in immunocompetent C57BL/6 mice. METHODS AND RESULTS: Multicolor flow cytometric analyses were used to phenotype and characterize immune infiltrating cells within established cerebellar tumors. We observed significantly higher percentages of dendritic cells, infiltrating lymphocytes, myeloid derived suppressor cells and tumor-associated macrophages in murine SHH model tumors compared with Group 3 tumors. However, murine Group 3 tumors had higher percentages of CD8+ PD-1+ T cells within the CD3 population. PD-1 blockade conferred superior antitumor efficacy in animals bearing intracranial Group 3 tumors compared to SHH group tumors, indicating that immunologic differences within the tumor microenvironment can be leveraged as potential targets to mediate antitumor efficacy. CONCLUSIONS: This is the first immunologic characterization of preclinical models of molecular subtypes of MB, and demonstration that response to immune checkpoint blockade differs across subtype classification. Our findings provide strong evidence for distinct immunophenotypes across subtypes of MB that have important value in the clinical application of relevant immunotherapeutic strategies targeting MB.
Successful Hematopoietic Stem Cells (HSC) Mobilization in Patients Who Fail Plerixafor Mobilization for Autologous Stem Cells Transplant (ASCT)
Authors: Tania Jain, Muthu Veeraputhiran, Simon Cronin, Zaid Al-Kadhimi, Muneer H. Abidi, Lois Ayash, Voravit Ratanatharathorn, Lawrence G Lum, Joseph P. Uberti, Abhinav Deol
Journal: Blood (2012)
Unlike Inactivating PTEN Mutations, Pharmacological Inhibition of PTEN Does Not Increase the Sensitivity of Multiple Myeloma Cells to Inhibition of the PI3K/Akt/mTOR Pathway.
Authors: Xiaojing Wang, Shuhong Zhang, Xiaodong Peng, Joe Garlich, Li Chen, Jing Liang, Sherif Shafik Farag
Journal: Blood (2007)
ATPS-03A SEMI-AUTOMATED PLATFORM FOR RAPID SIMULATION OF TTFIELDS DISTRIBUTION IN THE BRAIN
Authors: Ze'ev Bomzon, Noa Urman, Cornelia Wenger, Moshe Giladi, Aafia Chaudhury, Yoram Wasserman, Eilon Kirson, Yoram Palti
Journal: Neuro-Oncology (2015)

Tumor Treating Fields (TTFields) are low intensity alternating electric fields in the intermediate frequency range approved for the treatment of glioblastoma. TTFields are delivered through two pairs of transducer arrays placed on the patient's scalp. Preclinical studies show that TTFields efficacy increases with higher field intensity. Therefore optimizing the array layout on the head to maximize field intensity at the tumor is widely practiced. To better understand how TTFields distribute within the brain, realistic computational head models for performing simulation studies have been developed. A bottle-neck associated with such simulations is the placement of the transducer arrays on the virtual head. When placing arrays on patients, the disks naturally align parallel to the skin, and good electrical contact between the arrays and the skin occurs as the medical gel deforms to match the scalp contour. However, virtual models are made of rigidly defined surfaces. Therefore, placing the arrays on the model requires careful alignment of the array to the defined skin contour. Previously, array placement on virtual models was performed manually. However, this procedure is time consuming, limiting the rate at which different array layouts can be simulated. Here we present an automated method for rapidly generating simulations of TTFields distributions within the brain. For this purpose, we developed an algorithm that automatically places the arrays on a computational phantom. We integrated this algorithm into a simulation pipeline that uses a commercial Finite Element simulation package and a realistic head model. Using this pipeline we were able to rapidly simulate multiple array layouts on the head. Our simulations support the findings of prior studies demonstrating that the location of the arrays on the head impacts the field distribution within the brain, and that the array layout can be optimized to deliver maximal field intensities to desired regions within the brain.
ARE EXERCISE-BASED INTERVENTIONS EFFECTIVE IN REDUCING INJURIES IN TACKLE COLLISION BALL SPORTS? A SYSTEMATIC REVIEW
Authors: Nicola Sewry, Evert Verhagen, Mike Lambert, Willem van Mechelen, Wayne Viljoen, Clint Readhead, James Brown
Journal: British Journal of Sports Medicine (2017)

Background The injury burden in rugby union is relatively high compared to other team sports. Therefore rugby would benefit by having effective injury prevention programmes. Exercise-based interventions have successfully reduced injuries in soccer studies, but evidence on exercise-based interventions in tackle collision sports, such as rugby, is limited. Objective To systematically examine the evidence of exercise-based intervention programmes reducing injuries in tackle collision sports. Design Systematic review. Setting PubMed, EbscoHost and Web of Science were searched for articles published between January 1995 and December 2015. The methodological quality was assessed using an adapted Cochrane Bone Joint and Muscle Trauma Group quality assessment tool. Patients (or Participants) N/A as this is a systematic review abstract. Interventions (or Assessment of Risk Factors) The inclusion criteria were: 1) all types of randomised controlled trials and cohort studies 2) sporting codes: American, Australian and Gaelic football, rugby union and rugby league 3) participants of any age or sex 4) exercise-based, prehabilitative intervention, and 5) primary outcome was injury number or incidence. The exclusion criteria were: 1) full-text of the article was unavailable 2) the article was unavailable in English. Main Outcome Measurements Effectiveness, and injury number or incidence. Results Nine studies with a total of 3517 participants were included in this review. Seven studies showed a statistically significant decrease in their primary outcome (injuries). These studies included three different sporting codes and various age groups, making it difficult to be confident about the inferences. The two studies that had the highest methodological quality showed no statistically significant decrease in injury incidence following an exercise-based intervention. Conclusions There is a lack of consistent evidence from high-level studies that exercise-based interventions in tackle collision sports reduce injuries.
Nicotinamidephosphoribosyltransferase (NAMPT) Induces Ubiquitination of LEF-1 Transcription Factor By Deacetylation
Authors: Inna Zimmer, Bardia Samareh, Olga Klimenkova, Maksim Klimiankou, Murat Ünalan, Lothar Kanz, Karl Welte, Julia Skokowa
Journal: Blood (2015)
Purifying and Positive Selection Influence Patterns of Gene Loss and Gene Expression in the Evolution of a Plant Sex Chromosome System
Authors: Daisy Crowson, Spencer C.H. Barrett, Stephen I. Wright
Journal: Molecular Biology and Evolution (2017)

Sex chromosomes are unique regions of the genome, with a host of properties that distinguish them from autosomes and from each other. Although there is extensive theory describing sex chromosome formation and subsequent degeneration of the Y chromosome, the relative importance of processes governing degeneration is poorly understood. In particular, it is not known whether degeneration occurs solely as a direct result of inefficient selection due to loss of recombination, or whether adaptive gene silencing on the Y chromosome results in most degeneration occurring neutrally. We used comparative transcriptome data from two related annual plants with highly heteromorphic sex chromosomes, Rumex rothschildianus and Rumex hastatulus, to investigate the patterns and processes underlying Y chromosome degeneration. The rate of degeneration varied greatly between the two species. In R. rothschildianus, we infer widespread gene loss, higher than previously reported for any plant. Gene loss was not random: genes with lower constraint and those not expressed during the haploid phase were more likely to be lost. There was indirect evidence of adaptive evolution on the Y chromosome from the over-expression of Y alleles in certain genes with sex-biased gene expression. There was no complete dosage compensation, but there was evidence for targeted dosage compensation occurring in more selectively constrained genes. Overall, our results are consistent with selective interference playing the dominant role in the degeneration of the Y chromosome, rather than adaptive gene silencing.